ArticleJAMA network open2025
Parathyroidectomy and Cardiometabolic Risks in Patients With Primary Hyperparathyroidism.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiovascular Alterations in Primary Hyperparathyroidism: Associations with Risk Profile, Cardiac Structure, and Function.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Primary hyperparathyroidism (pHPT) is a common endocrine disorder linked to elevated parathyroid hormone and calcium levels, which may contribute to increased cardiometabolic risk. Objective: To evaluate the long-term cardiometabolic risks associated with pHPT and to assess whether parathyroidectomy is associated with reduced incidence of these outcomes. Design, Setting, and Participants: This retrospective cohort study used data from Clalit Health Services, Israel's largest health care organization. A total of 50 199 patients diagnosed with pHPT between January 1, 2000, and November 29, 2023, and 150 265 matched controls (matched 1:3 by age, sex, and socioeconomic status) were included. Patients with secondary hyperparathyroidism were excluded. Among patients with pHPT, 6654 underwent parathyroidectomy. Duration of follow-up was as long as 15 years. Data were analyzed from November 1, 2024, to April 1, 2025. Exposures: Diagnosis of pHPT and parathyroidectomy. Main Outcomes and Measures: Incidence of hypertension, type 2 diabetes (T2D), cardiovascular disease (CVD), and cerebrovascular accidents (CVA). Events were analyzed using Kaplan-Meier curves and multivariable-stratified Cox proportional hazards regression models adjusted for Charlson Comorbidity Index, body mass index, and ethnicity. Results: A total of 200 464 individuals were included (median age, 66 [IQR, 55-75] years; 136 884 [68.3%] female), comprising 50 199 patients with pHPT and 150 265 matched control individuals. Patients with pHPT exhibited an elevated long-term risk of hypertension (adjusted hazard ratio [AHR], 1.22; 95% CI, 1.17-1.33; P < .001), T2D (AHR, 1.07; 95% CI, 1.01-1.16; P = .02), CVD (AHR, 1.28; 95% CI, 1.21-1.42; P < .001), and CVA (AHR, 1.22; 95% CI, 1.17-1.33; P < .001) compared with controls. Between patients who underwent parathyroidectomy and those who underwent nonsurgical management, parathyroidectomy was associated with a reduced risk of T2D only, with the incidence decreasing from 15.18 (95% CI, 14.58-15.81) to 10.77 (95% CI, 9.80-11.83) per 1000 person-years (AHR, 0.56; 95% CI, 0.30-0.89; P = .002). Conclusions and Relevance: The findings of this cohort study suggest that pHPT is associated with increased long-term cardiometabolic risks. Parathyroidectomy may be associated with reduced incidence of T2D, supporting consideration of surgical intervention in appropriate patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.